Crystec is pleased to announce that the company will be attending the BIO International Convention 2026, taking place from 22–25 June 2026 in San Diego.
During the event, Crystec CEO Paul Thorning will be meeting with biotech and pharmaceutical companies to discuss how Crystec’s proprietary modified supercritical anti-solvent (mSAS®) particle engineering platform can address complex drug development challenges.
Crystec works with companies developing both small molecule and large molecule therapeutics, helping to enhance bioavailability, improve dissolution performance, optimise stability, and enable more effective drug delivery. The company’s mSAS® technology offers precise control over particle size, morphology, and solid-state properties, supporting the development of difficult-to-formulate drug candidates across a range of therapeutic areas and delivery routes.
The BIO International Convention provides an important opportunity to connect with industry partners, innovators, and drug developers seeking advanced formulation and particle engineering solutions.
Companies interested in arranging a meeting with the Crystec team during BIO 2026 can do so via the BIO Partnering™ platform: